Global Diabetes Medicine Sales show notable variability by country. In 2024, Canada leads with $3.78 billion, followed by Italy at $1.45 billion and Australia at $0.93 billion. Smaller markets like Croatia, Portugal, Denmark, Slovakia, New Zealand, and Latvia exhibit sales ranging from $0.5896 billion down to $0.0372 billion. In 2023, Canada showed a significant year-on-year growth of 15.25%, New Zealand had an 18.86% increase, and Australia saw a rise of 10.77%. On average, over the last five years, these countries have displayed a continuous upward trend in diabetes medicine sales, reflecting the growing prevalence and treatment efforts worldwide.
Future trends to watch for include technological innovations in diabetes care, increased access to medication in developing countries, and potential impacts of healthcare policy changes. As the global burden of diabetes continues to rise, there will be heightened demand for advanced medicines and more comprehensive care solutions, possibly leading to higher market projections across various regions.
Top countries in Diabetes Medicine Sales by Country
| # | 9 Countries | Million US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Canada | 3,780 | 2023 | +14.14% | +15.25% | View data |
| 2 | 2 Italy | 1,450 | 2023 | +2.14% | +5.34% | View data |
| 3 | 3 Australia | 930 | 2023 | +10.37% | +10.77% | View data |
| 4 | 4 Croatia | 589.6 | 2023 | +2.47% | +3.43% | View data |
| 5 | 5 Portugal | 563.1 | 2023 | +3.89% | +8.21% | View data |
| 6 | 6 Denmark | 240.4 | 2023 | +3.26% | +3.62% | View data |
| 7 | 7 Slovakia | 106 | 2023 | +3.21% | +5.19% | View data |
| 8 | 8 New Zealand | 94.4 | 2023 | +21.03% | +18.86% | View data |
| 9 | 9 Latvia | 37.2 | 2023 | +3.91% | +6.86% | View data |
